	US 12,275,970 B2
	Optimized factor IX gene
Siyuan Tan, Lexington, MA (US); Robert T. Peters, Needham, MA (US); and Tongyao Liu, Lexington, MA (US)
Assigned to BIOVERATIV THERAPEUTICS INC., Waltham, MA (US)
Filed by Bioverativ Therapeutics Inc., Waltham, MA (US)
Filed on Oct. 1, 2020, as Appl. No. 17/060,759.
Application 17/060,759 is a division of application No. 15/323,302, granted, now 11,008,561, previously published as PCT/US2015/038678, filed on Jun. 30, 2015.
Claims priority of provisional application 62/168,565, filed on May 29, 2015.
Claims priority of provisional application 62/019,069, filed on Jun. 30, 2014.
Prior Publication US 2021/0115425 A1, Apr. 22, 2021
Int. Cl. C12N 9/64 (2006.01)

CPC C12N 9/644 (2013.01) [C12Y 304/21022 (2013.01); C07K 2319/31 (2013.01); C12N 2800/22 (2013.01)]

15 Claims

1. A method of increasing expression of a polypeptide with Factor IX activity in a subject, comprising administering to a subject in need thereof, an isolated nucleic acid molecule or a vector comprising the isolated nucleic acid molecule, wherein the isolated nucleic acid molecule comprises a nucleotide sequence selected from the group consisting of:

(i) a sequence at least 85% identical to SEQ ID NO: 1;

(ii) a sequence at least 95% identical to SEQ ID NO: 54;

(iii) a sequence at least 96% identical to SEQ ID NO: 55;

(iv) a sequence at least 99% identical to SEQ ID NO: 56;

(v) a sequence at least 94% identical to SEQ ID NO: 57; and

(vi) a sequence at least 94% identical to SEQ ID NO: 58,

wherein the nucleotide sequence encodes a polypeptide with Factor IX activity, and wherein the expression of the polypeptide is increased relative to a reference nucleic acid molecule comprising SEQ ID NO: 2 or a vector comprising the reference nucleic acid molecule.